Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $16.75.

FOLD has been the topic of a number of recent research reports. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Wells Fargo & Company reduced their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics in the fourth quarter worth about $29,000. Covestor Ltd increased its stake in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Amicus Therapeutics in the 4th quarter worth about $59,000. GAMMA Investing LLC grew its position in shares of Amicus Therapeutics by 1,610.8% during the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 7,007 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Amicus Therapeutics during the fourth quarter worth about $79,000.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $7.20 on Friday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a market cap of $2.21 billion, a PE ratio of -40.00, a P/E/G ratio of 1.51 and a beta of 0.79. The company's fifty day simple moving average is $8.21 and its 200-day simple moving average is $9.42. Amicus Therapeutics has a 52 week low of $6.20 and a 52 week high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.